Please login to the form below

Not currently logged in
Email:
Password:

FDA declines approval for Eisai's Aricept

Eisai has received a complete response letter from the US Food and Drug Administration declining approval for the transdermal patch formulation of Eisai's Alzheimer's treatment Aricept

Eisai has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) declining approval for the transdermal patch formulation of Eisai's Alzheimer's treatment Aricept (donepezil hydrochloride).

The FDA has requested more information regarding the formulation and usage of the form of treatment.

Eisai has said it will collaborate with its US partner, Teikoku Pharma, and work with FDA to assess the complete response letter and determine next steps.

Teikoku developed the transdermal patch formulation of Aricept based on licence agreements with Eisai.

In June 2010, Teikoku submitted a new drug application to the FDA seeking approval to use the specific formulation of Aricept in the treatment of mild, moderate and severe stages of Alzheimer's disease.

26th April 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

The big issue
Whether you want to lead or follow, you need to understand the elephant in the C-suite...
INFOGRAPHIC 02: The Importance of clinical study websites
Here’s a infographic of why clinical study websites are important to patient recruitment and retention strategies…...
Working with, Advocating for, and Empowering Patients
A holistic view of how to work with patients virtually...

Infographics